Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P9T4 | ISIN: US8112922005 | Ticker-Symbol: 135A
Tradegate
06.06.25 | 19:17
0,813 Euro
+2,14 % +0,017
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
SCYNEXIS INC Chart 1 Jahr
5-Tage-Chart
SCYNEXIS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,7600,80006.06.
0,7700,82106.06.

Aktuelle News zur SCYNEXIS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
Leser Medien
28.05.Scynexis says GSK on hook for $10M payment after phase 3 Brexafemme trial starts back up18
28.05.SCYNEXIS resumes Phase 3 antifungal study after FDA lift1
28.05.SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study355First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical holdResumption of dosing in this study triggers a $10M milestone payment from GSK plus an additional $20M milestone...
► Artikel lesen
15.05.SCYNEXIS GAAP EPS of -$0.11 beats by $0.08, revenue of $0.26M beats by $0.12M22
15.05.SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update137Ibrexafungerp clinical hold lifted by the FDA. SCYNEXIS working to resolve a disagreement with GSK involving the restart of the MARIO study. GSK remains committed to the commercialization of Brexafemme.Hansoh...
► Artikel lesen
SCYNEXIS Aktie jetzt für 0€ handeln
15.05.SCYNEXIS INC - 10-Q, Quarterly Report1
13.03.SCYNEXIS GAAP EPS of -$0.44 misses by $0.98, revenue of $3.75M misses by $63.25M1
12.03.SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update752The Phase 1 trial of the second-generation triterpenoid antifungal SCY-247, initiated in December of 2024, continues and results are expected in Q3 of 2025.Four presentations for SCY-247 were accepted...
► Artikel lesen
12.03.SCYNEXIS INC - 10-K, Annual Report1
18.12.24SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections224JERSEY CITY, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant...
► Artikel lesen
06.11.24SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update187Clinical study reports for the FURI, CARES and NATURE trials in refractory or resistant invasive fungal infections were delivered to GSK, triggering a $10 million development milestone payment to...
► Artikel lesen
08.08.24SCYNEXIS Reports Second Quarter 2024 Financial Results and Provides Corporate Update247Clinical study reports for the FURI, CARES and NATURE trials in refractory or resistant invasive fungal infections were delivered to GSK, triggering a $10 million development milestone payment to...
► Artikel lesen
23.07.24SCYNEXIS To Receive $10 Mln Milestone Payment From GSK For Completed Clinical Study Report419LONDON (dpa-AFX) - SCYNEXIS Inc. (SCYX) announced it will receive a $10 million development milestone payment from GSK under their license agreement for ibrexafungerp. The milestone payment...
► Artikel lesen
13 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1